Importantly, some molecularly defined subgroups of patients have been identified which have an improved prognosis (8) and benefit from these recently developed agents, e.g., combined BRAF/MEK inhibition using the kinase inhibitors dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (9). This evidence concerns the gene BRAF and melanoma.